N/A
Manufactured by Westminster Pharmaceuticals, LLC
36,206 FDA adverse event reports analyzed
Last updated: 2026-04-14
THEOPHYLLINE ANHYDROUS is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Westminster Pharmaceuticals, LLC. The most commonly reported adverse reactions for THEOPHYLLINE ANHYDROUS include DYSPNOEA, ASTHMA, PNEUMONIA, WHEEZING, VOMITING. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for THEOPHYLLINE ANHYDROUS.
Out of 11,980 classified reports for THEOPHYLLINE ANHYDROUS:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 36,206 FDA FAERS reports that mention THEOPHYLLINE ANHYDROUS. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DYSPNOEA, ASTHMA, PNEUMONIA, WHEEZING, VOMITING, COUGH. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Westminster Pharmaceuticals, LLC in connection with THEOPHYLLINE ANHYDROUS. Always verify the specific product and NDC with your pharmacist.